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Background: A Phase II Clinical Trial reviewed the performance (morbidity and
calcification) of the tissue-engineered ADAPT® bovine pericardial scaffold (CardioCel®)
in pediatric patients (n = 30) with congenital cardiac defects. In that study, CardioCel®
demonstrated no graft-related morbidity and mortality in 25 patients, over 12
months. Five patients died due to non-graft-related events. Echocardiography revealed
hemodynamically stable repairs with no calcification of the scaffold. Magnetic resonance
imaging (MRI) at 12 months in 10 patients confirmed the absence of calcification. These
patients were followed up for further up to 10 years. We present the results of this
retrospective review of these patients that were followed for further medium to long-term
(median 7.2 years, 25%: 3.6 years 75%: 9.25 years) postoperatively in these patients.
Methods: Between April 2008 and September 2009, CardioCel® was implanted in
30 patients with congenital cardiac defects. Efficacy measures included graft-related
mortality, morbidity and haemodynamic abnormalities. Calcification was assessed by
standard 2D-M mode echocardiography and MRI at 12 months. Medium to long-term
assessment included routine clinical assessments and echocardiography.
Results: Median age at surgery was 18 months (27 days−13 years). Twenty-five
patients (142 patient years) were followed for up to 10 years. The 10-year survival rate
is estimated as 86.9% (95% CI 71.4–100.0%) over the entire follow-up period. One
patient was lost to follow-up. No graft-related mortality was encountered up to a median
follow-up of 7.2 years. Two patients died (pacemaker complications >5 years and
arrhythmia >7 years postoperatively). No graft failure, thromboembolic events, infections
or device-related reinterventions were recorded. Non-significant residual leaks occurred
in 3 patients. Echocardiography demonstrated the absence of calcification in all implants.
Conclusion: The tissue-engineered ADAPT® bovine pericardial scaffold demonstrated
excellent medium to long-term performance (up to 10 years) when used as a scaffold for
Neethling et al. Performance of CardioCel
repair of congenital cardiac defects in children. Durability, acellularity, biostability and
non-calcifying potential of CardioCel® makes it a very attractive tissue for congenital
cardiac repair procedures.
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INTRODUCTION
Since 1977, a variety of bioprosthetic substitutes have been used
for pediatric cardiac repairs such as bovine and porcine
pericardium fixed with glutaraldehyde, synthetics such
as Dacron R©, cryopreserved homografts and autologous
pericardium, fresh or treated with glutaraldehyde (1, 2).
Some of these materials failed due to intimal hyperplasia,
calcification, shrinkage with less pliability, resulting in a
compliance mismatch with surrounding native tissue (3).
Calcification of Dacron and xenogeneic substitutes fix with
glutaraldehyde after implantation is well-known while fresh
pericardium tends to dilate with resulting aneurysm formation in
high pressured areas (3, 4) and shrinkage of extended valve leaflet
augmentation (5).
Bovine pericardium fixed with glutaraldehyde tends to
degenerate when these implants become rigid due to calcium
deposits and develop changes in the structural integrity (shape
and size) after implantation which eventually causes failure of
these grafts. Toxicity caused by residual glutaraldehyde (6) and
induced immune responses of the recipient (7) tend to be the
main causes responsible for degeneration and calcification of
these implants.
While the atrioventricular septal defect (ASD) and ventricular
septal defect (VSD) have a low incidence of complications after
septal closure, more significant adverse events such as thrombus
formation on synthetic matrices (8), aneurysms occurring in
biological substitutes (9) and dehiscence of calcified patches have
been well published (10).
The present study was performed to assess the performance
of the tissue-engineered ADAPT R©-treated bovine pericardial
scaffold over a mid-term follow up period extending to 10 years
in a series of congenital cardiac repairs.
PATIENTS AND METHODS
In the prospective, non-randomized Phase II Clinical study, a
range of congenital cardiac anomalies in 30 pediatric patients
were repaired with ADAPT R©-treated tissue-engineered bovine
pericardial scaffold (Cardiocel R©, ADMEDUS Pty Ltd, Perth
Western Australia) from April 2008 to September 2009 at
the Universitas Hospital, Faculty of Health Science, University
of Free State in Bloemfontein, South Africa. The study was
registered (clinical registration number ETOVS NR 27/7) and
approved by the Ethics Committee of the Faculty of Health
Science, University of Free State, Bloemfontein, South Africa.
Formal consent was obtained from all patients next of kin
or legal representative. Patients were eligible for inclusion if
ADAPT R©-treated tissue-engineered Cardiocel R© was used as
a bioprosthetic substitute during repair of congenital heart
defects using cardiopulmonary bypass. A range of congenital
cardiac repairs included ASD, VSD, atrioventricular septal
defect (AVSD), aortic root enlargement and right ventricular
outflow tract (RVOT) reconstruction. All repair procedures were
performed by the same two surgeons. Patients were followed for
12 months during the initial study period and these results been
previously published (11).
The ADAPT R©-treated tissue-engineered Cardiocel R©
scaffold is manufactured from bovine pericardium which is
certified as BSE (bovine spongiform encephalopathy) free. The
manufacturing processes of Cardiocel R© consists of several
tissue engineering steps which remove phospholipids, cells
and cell remnants within the scaffold, nucleic acids (DNA,
RNA) and α-Gal epitopes. An ultra-low concentration of
chemically engineered, monomeric glutaraldehyde is used to
cross-link the scaffold to minimize the potential cytotoxicity
levels of glutaraldehyde. An additional anti-calcification process
ADAPT R© process (ADMEDUS Pty Ltd proprietary) is applied
to further reduce the glutaraldehyde cytotoxicity to zero levels.
Sterilization of the Cardiocel R© scaffold is performed with a
non-glutaraldehyde solution and stored in the same solution
which provides additional anti-calcification properties (11).
This study is a retrospective review of the mid-term
follow up those patients who underwent surgical repair of a
congenital heart defect, using tissue-engineered CardioCel R©
bovine pericardium up to 10 years of follow up. The medical
records of each patient were reviewed, and the following patient
and scaffold-related data collected: gender, age at operation,
primary cardiac diagnosis, number, type and location of patches,
and echocardiographic assessment reports.
All patients (24/30) received routine echocardiographic
assessments during each follow-up visit which were reported
by two experienced pediatric cardiologists. Calcification
was assessed by standard 2D-M mode echocardiography
(HP3000, Hewlett Packard, JHB, South Africa) by the
most experienced sonographer (16 years of experience in
pediatric echocardiography) who was blinded from the clinical
information. A numeric scale of 0 (no visible calcification), 1
(mild, focal calcification), or 2 (moderate to severe dispersed
calcification) based on increased echo density differences
between the site of implantation and surrounding tissue was
used to identify the level of calcification.
The primary endpoints included death of the patient, failure
of the tissue scaffold resulting in reoperation and/or any form of
scaffold-related reintervention.
Statistical Analysis
Patient demographic and baseline characteristics were
summarized as frequencies and percentages for categorical
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TABLE 1 | Patient demographics and baseline characteristics.
All implants, n (%) 30 (100)
Median age, months (range) 18 (27 days−13 years, 3 months)






ASD and VSD 1 (3)
VSD and RVOT 4 (13)
ASD, VSD and RVOT 1 (3)
Vascular patch (aorta) 2 (7)
VSD and coarctation 2 (7)





ASD, Atrial septal defect; VSD, Ventricular septal defect; AVSD, Atrioventricular septal
defect; RVOT, Right ventricular outflow tract.
variables and continuous variables were expressed as median
(range). As the cohort is small, statistical analysis was limited
to a Kaplan-Meier plot containing the survival distribution of
24 patients and a Cox regression performed on the time to last
follow up or survival. The 10-year survival rate is presented
with a 95% confidence interval to capture the uncertainty in the
estimate. R and the package survival were used for analysis.
RESULTS
A total of 34 CardioCel R© devices were implanted in 30 patients.
The baseline patient characteristics and distribution of cardiac
anomalies are summarized inTable 1. Themedian age at the time
of surgery was 18 months (range, 27 days to 13 years, 3 months).
Cardiac diagnoses included VSD (n = 14, 47%), VSD +
RVOT (n = 4, 13%), AVSD (n = 3, 10%), trans-position of the
great arteries (TGA) (n = 2, 7%), double outflow right ventricle
(DORV) (n = 2, 7%), truncus arteriosus (TA) (n = 2, 7%), aortic
arch (Ao) (hypoplastic arch+ coarctation n= 1, 3%; coarctation
n = 1, 3%) and ASD (n = 1, 3%). Concomitant procedures
included mitral valve plasty in one patient (3%).
Follow-up was available on 24 patients (80%). The median
follow-up was 7.2 years (range 1.3–10.6). Seven patients (28%)
had follow up periods between 1 and 5 years and 17 (68%)
patients were followed up for between 5 and 10 years (Table 2).
One patient was lost to follow-up after the initial clinical trial
period of 12 months. The geographical relocation and difficulties
with traveling from remote areas were cited as reasons for the lack
of follow-up, a known difficulty for clinical trials in South Africa.
Stable non-haemodynamically significant small residual VSDs
between 2.0 and 3.1mm were detected during echocardiography
assessments in 3 (10%) patients during follow up.
TABLE 2 | Patient follow-up 1–10 years.
Diagnosis Application Follow-up (yrs)
Follow-Up 1–5 years (n = 7)







Follow-Up 5–10 years (n = 17)
Tetralogy of fallot VSD + RVOT Trans-annular Patch 10.4
DORV Trans-annular Patch 7.0
Truncus art VSD 9.4
TGA VSD 9.3
TGA VSD + Transannular Patch 5.2
Ao Coarctation + VSD Aortic patch + VSD 9.4
Ao Coarctation Aortic patch 8.5
AVSD + Mitral valve stenosis AVSD + Mitral valve repair 9.5
AVSD AVSD 9.1





VSD + PDA VSD 9.2
VSD VSD 5.2
VSD VSD 7.7
ASD, Atrial septal defect; VSD, Ventricular septal defect; AVSD, Atrioventricular septal
defect; DORV, Double outlet right ventricle; TGA, Transposition of the great arteries.
None of the transannular patches in the LVOT (n = 2)
or RVOT (n = 4) demonstrated flow obstruction during
echocardiographic assessment.
No surface thickening, structural leaks or calcification
in any of these implants were detected. There were no
thromboembolic events, no device-related re-operations,
no device replacements or no graft failures in any patients.
One patient (AVSD + mitral valve plasty) had a mitral valve
replacement 4 years after the initial procedure. Examination
of the AVSD repair area during the mitral valve procedure
revealed an intact repair without any surface thickening,
indications of dehiscence or obstruction. Freedom from
reintervention at 5 and 10 years is 0.94 (95%CI: 0.84–1.00)
(Figure 1).
Two patients died due to comorbid non-graft-related
events. One patient (TGA + VSD) died at 5.2 years
postoperatively due to acute pacemaker failure and one
patient (DORV) died 7 years postoperatively due to
uncontrolled arrythmia. Freedom from death at 5 and
10 years is 1.00 (95%CI: 1.00–1.00) and 0.71 (95%CI:
6.99–1.00), respectively (Figure 2). No patient underwent
reoperation for a CardioCel related problem. Calcification
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FIGURE 1 | Kaplan-Meier plot of freedom from reintervention of 24 patients.
Ninety five percentage of confidence interval (dashed lines) at 10 years.
FIGURE 2 | Kaplan-Meier plot of the survival distribution of 24 patients. Ninety
five percentage of confidence interval (dashed lines) at 10 years.
of the implant was not detected on echocardiography in
any patient.
DISCUSSION
In this single-center, retrospective study, we have
demonstrated medium to long term durability, efficacy
and the absence of calcification of the tissue-engineered
ADAPT R© bovine pericardial scaffold (CardioCel R©)
when used to repair a variety of congenital heart
defects in pediatric patients followed for up to
10 years.
The use of several synthetic and bioprosthetic materials
(homografts, pericardial xenografts and porcine intestinal sub-
mucosa) for cardiovascular applications and the repair of
congenital heart deformities have been well-documented (12).
To our knowledge, none of these materials have specifically
been followed over extended implantation time. The ideal
characteristics of these bioprosthetic substitutes should include
easy handling, efficient pliability to allow optimal manipulation
without being too flexible that would allow folding on itself,
stable after implantation, resistant to calcification and non-
sensitizing to the immune system. At present, none of the
available patch materials have all these characteristics (13). Fresh
autologous pericardium tends to be an attractive option due to
advantages such as immediate availability, low-cost, the absence
of donor-derived pathogens and non-immunogenicity (4). It
provides satisfactory long-term results when used for repair
of simple congenital defects and for aortic valve repair when
rapidly fixed with glutaraldehyde (5, 14). However, when used
without glutaraldehyde fixation, it shrinks, develops fibrosis
and tends to stretch when exposed to high cardiovascular
pressure, with reports of aneurysm formation at the site
of the repair (13). The main advantage of glutaraldehyde
fixation is that it improves the biostability of autologous and
xenogeneic pericardium through collagen crosslinking, but with
the potential consequences of residual toxic aldehydes which
could result in late calcification (5, 15). However, structural
degeneration and dystrophic calcification remain limiting factors
in terms of the longevity and clinical effectiveness of these
bioprosthetic substitutes (11, 12, 16). The inability of these
materials to grow with the recipient tissue, loss of tensile
strength over extended implantation time and inability to
remodel or regenerate further reduce the potential for long-term
performance. Bioprosthetic substitutes are sometimes associated
with a risk of the infection and the formation of aneurysms, in
addition to the cytotoxic effects of various chemical cross-linking
agents (17).
To date, most of the retrospective studies with bovine
pericardial patches in congenital cardiac surgery are
limited to case reports or short-term results (11, 13).
Several case reports of complex congenital cardiac repairs
with CardioCel R© demonstrated favorable outcomes in
terms of handling characteristics, durability and clinical
efficiency (18–20).
In addition, short to medium term retrospective studies
with Cardiocel have also demonstrated positive outcomes in
terms of performance, no calcification and efficacy (21–24). A
less favorable outcome (freedom from reoperation 57% at 36
months) was reported in a single center study of CardioCel R©
used in aortic valve reconstruction in young children (25).
On the other hand, a more promising outcome was reported
by Bell et al. (23) with freedom from reintervention in 135
patients (140 procedures and 195 implants) at 36 months of
94% (CI 89–97) without any evidence of calcification after
echocardiographic and radiological assessment in any of these
patients. Similar results were reported in a multi-center study
(Brisbane, Australia; and Leicester and Bristol, United Kingdom)
with an overall freedom from reintervention at 3 and 5
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years after implantation of 96% (95% confidence interval, 93–
98%) (24).
One of the most important outcomes with CardioCel R© is
clinical evidence of early remodeling (scattered capillary vessels
with new collagen fibers and formation of neointima) which
was demonstrated in explanted samples with implantation time
ranging from 67 to 502 days (21).
In the present study, the medium to long-term
performance of CardioCel R©, in a variety of congenital
cardiac repairs have retrospectively been assessed between
1 and 10 years. The most outstanding findings of this
study were the absence of graft-related adverse events
and calcification.
LIMITATIONS
This study has all the limitations of a small retrospective study.
It is a single-center study without a control group. The main
limitation of the study was a small number of patients and
follow-up was incomplete in some patients. Another limiting
factor was the heterogenous patient groups based on the different
areas of application. The use of echocardiography to detect
calcification was also be regarded as a limitation in view of the
scoring system which assesses semi-quantitatively the presence
of hyperechoic zones or changes in echodensity as opposed
to a quantitative measurement with a computed tomography
(CT) scan.
CONCLUSION
In summary, this study shows that in these pediatric patients
with a range of congenital cardiac anomalies, followed for 1–
10 years, the tissue engineered ADAPT R© bovine pericardial
scaffold (CardioCel R©) demonstrated good biocompatibility and
durability. No graft-related calcification was observed, and there
was no graft-related morbidity or mortality reported.
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